Pizzato, Massimo
 Distribuzione geografica
Continente #
NA - Nord America 4.504
AS - Asia 1.604
EU - Europa 1.187
SA - Sud America 320
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 7.666
Nazione #
US - Stati Uniti d'America 4.451
SG - Singapore 674
IT - Italia 325
CN - Cina 315
VN - Vietnam 306
BR - Brasile 260
RU - Federazione Russa 185
UA - Ucraina 99
FI - Finlandia 97
DE - Germania 87
FR - Francia 84
GB - Regno Unito 72
LV - Lettonia 61
SE - Svezia 55
IN - India 52
HK - Hong Kong 49
KR - Corea 41
NL - Olanda 33
ID - Indonesia 29
CA - Canada 28
BD - Bangladesh 25
AR - Argentina 24
TR - Turchia 24
AT - Austria 18
IQ - Iraq 17
PL - Polonia 17
JP - Giappone 15
EC - Ecuador 13
MX - Messico 13
ZA - Sudafrica 12
ES - Italia 8
JO - Giordania 8
VE - Venezuela 8
CL - Cile 7
TN - Tunisia 7
BG - Bulgaria 6
CZ - Repubblica Ceca 6
PK - Pakistan 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
EG - Egitto 4
HU - Ungheria 4
KE - Kenya 4
LB - Libano 4
LT - Lituania 4
TW - Taiwan 4
AL - Albania 3
BY - Bielorussia 3
CH - Svizzera 3
CO - Colombia 3
CR - Costa Rica 3
GR - Grecia 3
IE - Irlanda 3
IL - Israele 3
JM - Giamaica 3
MA - Marocco 3
PY - Paraguay 3
TH - Thailandia 3
AU - Australia 2
AZ - Azerbaigian 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
IR - Iran 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
PH - Filippine 2
PS - Palestinian Territory 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BE - Belgio 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GM - Gambi 1
HN - Honduras 1
KG - Kirghizistan 1
LY - Libia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
PR - Porto Rico 1
RS - Serbia 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
UY - Uruguay 1
YT - Mayotte 1
Totale 7.666
Città #
Fairfield 508
Ashburn 502
Singapore 436
Chandler 281
Woodbridge 249
Seattle 229
Jacksonville 221
San Jose 207
Wilmington 192
Cambridge 176
Houston 167
Santa Clara 137
Dallas 133
Ann Arbor 108
Columbus 103
Trento 90
Moscow 87
Princeton 84
Ho Chi Minh City 83
San Mateo 81
Los Angeles 77
Council Bluffs 67
Hanoi 66
Beijing 65
New York 64
Riga 61
The Dalles 55
Lauterbourg 54
Helsinki 47
Munich 38
Boardman 36
Hong Kong 36
Seoul 36
Orem 30
Chicago 26
Como 26
San Diego 25
Milan 24
São Paulo 24
London 23
Rome 23
Da Nang 21
Jakarta 21
Dearborn 20
Buffalo 18
Chennai 18
Hefei 16
Redondo Beach 15
Warsaw 15
Montreal 14
Tokyo 14
Dong Ket 12
Frankfurt am Main 12
Brooklyn 11
Haiphong 11
Johannesburg 11
Vienna 11
Lappeenranta 9
San Paolo di Civitate 9
St Louis 9
Verona 9
Amsterdam 8
Falkenstein 8
Guangzhou 8
Poplar 8
Atlanta 7
Elk Grove Village 7
Hillsboro 7
Izmir 7
Mexico City 7
Mumbai 7
Nuremberg 7
Turin 7
Turku 7
Denver 6
Jinan 6
Rio de Janeiro 6
Sofia 6
Stockholm 6
Tashkent 6
Washington 6
Belo Horizonte 5
Biên Hòa 5
Brasília 5
Bremen 5
Dhaka 5
Düsseldorf 5
Fort Worth 5
Fremont 5
New Delhi 5
Phoenix 5
Quito 5
Salt Lake City 5
Shanghai 5
Toronto 5
Baghdad 4
Brno 4
Brugherio 4
Can Tho 4
Istanbul 4
Totale 5.480
Nome #
A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method 220
A bipartite structural organization defines the SERINC family of HIV-1 restriction factors 214
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation 213
SERINC5 as a new restriction factor for human immunodeficiency virus and murine leukemia virus 212
SARS-CoV-2 and the Host Cell: A Tale of Interactions 201
SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins 197
Galanin pathogenic mutations in temporal lobe epilepsy 197
Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior 177
The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists 175
Retroviral factors promoting infectivity. 174
Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve 171
Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26 171
The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild 170
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 168
The antagonism of HIV Nef to SERINC5 particle infectivity restriction involves the counteraction of virion-associated pools of the restriction factor 166
Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. 164
The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles 162
S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3 161
Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK. 156
Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents 155
Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration 152
Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. 150
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity 146
Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. 137
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. 134
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. 134
SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals 132
Effect of differential growth conditions on the dTTP pool size in herpes simplex virus-infected Vero cells. 132
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. 130
A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. 129
Progress with retroviral gene vectors. 125
Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry. 124
Viral particles imaging through evanescent wave scattering in a total internal reflection laser microscope 122
Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. 121
Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers. 113
Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. 113
Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. 113
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. 112
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. 112
Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. 112
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. 110
Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. 107
The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. 107
Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5 105
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine 104
MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. 101
A Conserved Acidic Residue in the C-Terminal Flexible Loop of HIV-1 Nef Contributes to the Activity of SERINC5 and CD4 Downregulation 99
Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. 97
Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity 95
Host Restriction Factors Modulating HIV Latency and Replication in Macrophages 91
The activity of Nef on HIV-1 infectivity. 91
Trends and symptoms of SARS-CoV-2 infection: a longitudinal study on an Alpine population representative sample 80
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. 79
Retrovirus vectors. 76
Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals 70
The impact of infection risk communication format on tourism travel intentions during COVID-19 69
Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol 67
Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity 57
A Two-Step Ion-Exchange Process for Modified Mechanical Reinforcement and Virucidal Functionalization of Glasses 40
Ten questions concerning dynamic sensory variation in salutogenic building design 12
Totale 7.824
Categoria #
all - tutte 32.074
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 511
Totale 32.585


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 0 0 0 0 0 0 53
2021/2022481 22 32 8 20 12 31 7 106 48 49 59 87
2022/2023607 63 68 6 69 52 87 9 54 113 35 31 20
2023/2024332 20 20 18 20 34 84 21 22 5 13 12 63
2024/20251.332 17 11 75 247 79 166 115 82 137 234 76 93
2025/20262.860 184 82 330 476 362 186 519 81 214 268 86 72
Totale 7.824